Navigation Links
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
Date:11/3/2008

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses synovial VEGF and bFGF gene expression. J Rheumatol 2008;35:2119- 28).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from treatment studies in a preclinical model of established rheumatoid arthritis demonstrated that daily oral administration of 2ME2 suppressed both clinical and radiographic indicators of joint inflammation and damage, including soft tissue swelling and bone erosion. The treatment benefits of 2ME2 were dose-dependent and associated with reduced joint expression of the prominent angiogenic growth factors, FGF-2 and VEGF, as well as decreased angiogenesis. The report further demonstrates both a delay in onset and decrease in severity of arthritis if 2ME2 treatment is started prior to disease initiation. These results indicate that 2ME2 may represent a novel agent for treatment of inflammatory autoimmune diseases such as rheumatoid arthritis and identify 2ME2 as a disease mod
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
2. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
3. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
4. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
5. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
6. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
7. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
8. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
10. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
11. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Brooding fishes take up nutrients from their own children 2First-in-class treatment for acute leukemia 2First-in-class treatment for acute leukemia 3Misuse of antibiotics not the only cause of resistance says report 10386 1Misuse of antibiotics not the only cause of resistance says report 10386 2VA Funding Reform Bill Clears Congress 59572 1VA Funding Reform Bill Clears Congress 59572 2Not Getting Enough Fruits and Vegetables 3F Think Frozen 21 Antioxidant rich Frozen Wild Blueberries are Convenient and Just As Nutritious As Fresh 59567 1Not Getting Enough Fruits and Vegetables 3F Think Frozen 21 Antioxidant rich Frozen Wild Blueberries are Convenient and Just As Nutritious As Fresh 59567 2